ClinicalTrials.gg
Not yet recruitingNCT06549335Updated Oct 15, 2024

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

A Phase 2 interventional study of Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in Follicular Lymphoma, sponsored by Ruijin Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Ruijin Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing zanubrutinib in Lymphoma, Follicular — 9 open to participants now, 11 under way, 1 of them phase 3. zanubrutinib · Lymphoma, Follicular.

Planned enrollment
4th of 13
66 · median 43
Started
2024
with 4 others
Phase 2
11 of 13
9 open now
Primary completion
2026-12
later than 1 of 10 live
Registered
7th of 13
by date
Lead sponsor
1 of 13
Ruijin Hospital

Among the 13 studies testing zanubrutinib in Lymphoma, Follicular, this one is the 4th largest by planned enrollment, is one of 5 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 7th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

9 of the 13 studies testing zanubrutinib in Lymphoma, Follicular are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing zanubrutinib in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This is a prospective, multiple-centers, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in high-risk treatment-naive patients with follicular lymphomas

03

Conditions studied

  • Follicular Lymphoma

Keywords

  • Zanubrutinib
  • Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
  2. Treatment naive
  3. Age ≥ 18 years
  4. Indications for treatment confirmed
  5. Identified as high-risk group by Follicular Lymphoma International Prognostic Index 2 (FLIPI2) at enrollment
  6. Must has in CT or PET-CT prior to treatment
  7. Considered suitable for ZGR regimens
  8. Informed consented

Exclusion criteria

Exclusion Criteria:

  • Transformed follicular lymphoma or 3B follicular lymphoma;
  • positive and / or HBcAb positive with HBV DNA titer; antibody positive with HCV-RNA; or positive
  • Any drug in the treatment plan
  • Pregnant or lactating women
  • Patients judged by other researchers to be unsuitable for inclusion in the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Experimental: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)

    Drug: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)

Interventions

  • DrugZanubrutinib, Obinutuzumab and Lenalidomide (ZGR)

    Drug pages: ZanubrutinibStudies of ZanubrutinibZanubrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ObinutuzumabStudies of ObinutuzumabObinutuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Induction therapy: The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles. Dosage: 1. Zanubrutinib, 160 mg bid, po, day 1-28; 2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6); 3. Lenalidomide, 25 mg qd, po, day 2-11. Maintenance therapy: 1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years; 2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Percentage of participants with overall response was determined on the basis of investigator assessments according to 2014 Lugano criteria

    Time frame: At the end of Cycle 6 (each cycle is 28 days)

Secondary outcomes

  1. Complete response rate (CR)

    Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

    Time frame: At the end of Cycle 6 (each cycle is 28 days)

  2. Partial response rate (PR)

    Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

    Time frame: At the end of Cycle 6 (each cycle is 28 days)

  3. Duration of response

    Time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with PET-CT.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  4. 2-year progression free survival rate

    progression-free survival was defined as the time from the date of first treatment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  5. 2-year overall survival rate

    progression-free survival was defined as the time from the date of first treatment until the date of the first documented day of death from any cause.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Dec 2026, 24 months later.

Of 151 non-industry phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 110. This study's planned 24 months is below that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartEst.
Dec 1, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06549335
Lead sponsor
Ruijin Hospital
Responsible party
Zhao Weili (First Deputy Director, Hematology Department, Ruijin Hospital) — Principal investigator
First posted
Aug 12, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 15, 2024

Study contacts

Weili Zhao, M.D. and Ph.D
Contact
zwl_trial@163.com
+862164370045 ext. 610707
Pengpeng Xu, M.D. and Ph.D
Contact
pengpeng_xu@126.com
+862164370045 ext. 610707

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Obinutuzumab · Lenalidomide

Start the discussion